Protocol J2G-OX-JZJF 
A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics 
of LOXO-292 in Healthy Adult Subjects
[STUDY_ID_REMOVED]
Approval date: 25 -Jan-2019
16. Appendices
16.1 Study Inf
ormation
16.1.1 Protocol and Protocol Amendments
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
1. ' celerion 
Translating Science to 
Medicine 
T,-anslating Soience a;o 
Medicine 
Protocol Clarification Letter for Celerion Study No.: CA27486 
Loxo 011cology, Jnc. Project No.: LOXO-RET-[ZIP_CODE] 
Date of Final J>rotocol: 25-Jan -2019 
Date of Protocol Clarification Letter: 25-Feb-2019 
A Phase I. Single-Ascend ing Dose Study to Evaluate the Safety, Tolerability, and Pharruacokine ·cs of 
.!:.?X0-:?11.'.!!!!!lthy_ A-d-u-l_t_s_u«b_J_'c_cts __________ , _____ ~----------· 
Per the final protocol, and as per Section l3.2.3, additional 12-lead electrocardiogram (ECGs) m y be taken at 
any ether time(s), if deemed necessary by [CONTACT_079] (Pl) or designee. As per equest of the 
Sponsor and PI, an additional safety ECG is to be performed at 3.[ADDRESS_1250992].dose on Day I for 11 subjects in 
Cohort 2 and Cohort 3. The event timing 1s to coincide with the anticipated maximum concen tion (Cmax) 
following a single dose of LOXO -292. 
Therefore, the below sections should read as follows: 
Section 6 Study Events Flow Chart 
A check mark should be added in the safety 12-lead ECG row on Day 1 at 3.5 hours (for Cohorts and 3 only). 
Section 13.2.3 ECG Monitoring 
Paragraph 3 of Section 13.2.3 is modified a,; follows (updates in bold) 
ECGs will be measured at Screening, at Check-in (Day-1), Day J (Hour 3.5), Days 2 and 5 pos ose, and at 
the EOT or ET (CRU discharge). ECGs will be obtained prior to and as close as possible to e scheduled 
blood draws if scheduled at the same time. 
The final protocol. 25-•Jan-[ADDRESS_1250993] cifi.ca,t.fooJet.tws heiJ.}.a_wtltt ,;;,,.i. ____ _ 
(r iDocuSigned by: 
11:'1~---· Name • P I I 
Pl J~~ -d11hJ)pprove this document 
Pl ~~3BJ 6~:~b~ AM EST 
Pl B79BAD69CBA 
(Pl !.tvID, CPI 
[INVESTIGATOR_893270] 
22-[ADDRESS_1250994], Northern Ireland 
Tel: 0044 (0) [PHONE_18519] • Fax: 0044 (0) [PHONE_18520] Pl 
Date 
25-Feb- 19 I 07 :58:12 ST 
Date 
Date 
age 1 of 1 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16. 1.[ADDRESS_1250995] No.: CA27486 
Sponsor Project No.: LOXO -RET -[ZIP_CODE] 
US IND No.: 133193 
GCP Statement  
This study is to be performed in full compliance with the protocol, Good Clinical Practices 
(GCP), and applicable r
egulatory requirements. All required study documentation will be 
archived as required by [CONTACT_12721]. 
Confidentiality Statement 
This document is confidential. It contains proprietary information of Loxo Oncology, Inc. 
and/or Celerion. Any viewing or disclosure of such information that is not authorized in 
writing by [CONTACT_132189], Inc. and/or Celerion is strictly prohibited. Such information may 
be used solely for the purpose of reviewing or performing this study. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
3celerion 
Translating Science to 
Medicine 
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
1 PROTO COL REVISION HISTORY 
125 January 2019 
by[CONTACT_976] ------I Final Protoco l 
Page 2 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 4 
CONF IDENTIAL CA27486 (LOXO-RET-1 8057) , Final Protocol , 25Jan2019 
2 PRINCIPAL INVESTIGATOR [INVESTIGATOR_78411] -SIGNATORIES 
A Phase I, Single-Ascending Dose Study to Evaluate the Safety , Tolerability , and 
Pharmacokinetics of LOXO-292 in Healthy Adult Subjects 
SPONSOR: 
SPONSOR'S 
REPRESENTATIVE : Loxo Oncology , Inc. 
[ADDRESS_1250996] 
South San Francisco, Californi a [ZIP_CODE] , [LOCATION_003] 
~=="""=='_, MD, PhD 
Pl o Loxo Oncology , Inc. 
Mob ile Pl 
E-maiI:PI 
(E: DocuS1 qned bv: 
U.gnajili@.Jame : ___ _ 25-Jan-19 I 09:57:[ADDRESS_1250997] 
Date 
LSigning Reason : I approve this document 
Signing Time 1/25/2019 12:57 :[ADDRESS_1250998] 
01A6C830EC5145848DE60879BAD69CBA 
Page 3 
LOXO -RET -[ZIP_CODE] ; CA27486; 16.1.1 Protoco l and Protocol Amendments 5 
CONFIDENTIAL CA27486 (LOXO-RET-[ZIP_CODE]) , Final Protocol , 25Jan2019 
A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and 
Pharmacokinetics of LOX0-[ADDRESS_1250999] 
Tel.: ~ P;;;;I ===== Fax: Pl _____ ____. 
Pl 
Signature r I 
Printed Name [CONTACT_893311] 4 
LOXO-RET -[ZIP_CODE] ; CA27 486; 16.1.1 Protocol and Protocol Amendmen ts 6 
CONFIDE NTIAL CA27486 (LOXO-RET-1 8057), Final Protocol , 25Jan2019 
[ADDRESS_1251000] 
Protocol Author 
Certified Clinical Laborator y 
Bioanalytical Laborator y for 
LOX0-292 efax: +l 203 643- 2013 
E-mail: [EMAIL_814] 
~ Pl===::--' ~iD,PhD 
Pl o Loxo Oncology, Inc. 
Mob ile: 
E-mail: Pl 
Pl 
Pl , Clinical Operations 
Loxo Oncology, Inc. 
Tel.: Pl 
E-mail: Pl 
Pl PhD 
Semor Scientist, P rotoco l and Medical Writer 
Celerion 
I 
Pl 
Pl freland 
Tel.: Pl 
Fax: PI 
E-mail: Pl 
Celerion 
[ADDRESS_1251001]: 
Tel.: Pl ext. Pl 
Fax:PI -~ 
Alturas Analytics, Inc. 
Altura s Technology Park 
1324 Altura s Dri ve 
Moscow , Idaho [ZIP_CODE], [LOCATION_003] 
Tel.: + [PHONE_18521] 
Page 5 
LOXO -RET -[ZIP_CODE]; C A27486; 16.1.1 Protocol and Protocol Amendme nts 7 
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251002] 
Montreal, Quebec H4M 2N
8, Canada  
Tel.: +[PHONE_15837] 
Fax: +[PHONE_15838] 
 
and/or 
 
Celerion  
[ADDRESS_1251003], Nebraska [ZIP_CODE], [LOCATION_003] 
Tel.: +[PHONE_15839] 
Fax: +[PHONE_15840] 
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
8
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 7 4 TABLE OF CONTENTS  
1 P
ROTOCOL REVISION HISTORY  ............................................................................. 2 
2 PRINCIPAL INVESTI
GATOR AND SPONSOR – SIGNATORIES  ......................... 3 
3 ADDITI
ONAL KEY CONTACTS FOR THE STUDY ................................................ 5 
4 TABLE OF CONTENTS  ................................................................................................. 7 
5 SYNOPSIS  ....................................................................................................................... 10 
6 STUDY 
EVENTS FL
OW CHART  ............................................................................... 14 
7 ABBREVI
ATIONS  ......................................................................................................... 17 
8 INTRODUCTION........................................................................................................... 20
 
8.1 Background ............................................................................................................. 20 
8.1.1 LOXO -
292 ................................................................................................ 20 
8.2 Rationale  .................................................................................................................. 
22 
8.2.1 Rational e for thi
s Study and Stud y Design ............................................... 22 
8.2.2 Rationale for the Dose Selection and Dose Regimen  ............................... 22 
8.2.3 Rationale for P
rimary Endpoints .............................................................. 23 
8.3 Risks and/or Benefits to Subjects ............................................................................ 24 
9 OBJECTIVES AND ENDPOINTS  ............................................................................... 25 
9.1 Objectives  ................................................................................................................ 25 
9.2 E
ndpoints ................................................................................................................. 25 
10 S
TUDY DESIGN ............................................................................................................. 26 
10.1 Overall Study Design and Plan  ............................................................................... 26 
10.1.1 Confinement, Retur
n Visits, and Follow- Up ............................................ 26 
10.1.2 End of Study Defini
tion ............................................................................ 27 
11 STUDY POPULATION ................................................................................................. 28 
11.1 Inclusion Criteria  ..................................................................................................... 28 
11.2 Exclusion Cr
iteria  .................................................................................................... 29 
11.3 Early Termin
ation of Subjects from the Study  ........................................................ 32 
11.4 Study Restrictio
ns ................................................................................................... 32 
11.4.1 Prohibitions and C
oncomitant Medication ............................................... 32 
11.4.2 Meals  ......................................................................................................... 33 
11.4.3 Activity  ..................................................................................................... 34 
12 TREA
TMENTS ............................................................................................................... 35 
12.1 Tre
atments Admin
istered  ........................................................................................ 35 
12.2 Dose Modificati
on ................................................................................................... 35 
12.3 Method of Treatment Assignment ........................................................................... 35 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
9
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 8 12.4 Blinding ................................................................................................................... 36 
12.4.1 Dos
e Escalation Criteria and Stoppi[INVESTIGATOR_1869] ........................................... 36 
12.5 Treatment Compliance  ............................................................................................ 37 
13 STUDY ASSESSMENTS
 AND PROCEDURES  ......................................................... 38 
13.1 Screening  ................................................................................................................. 38 
13.2 Saf
ety Assess
ments  ................................................................................................. 38 
13.2.1 Physical Examina
tion................................................................................ 38 
13.2.2 Vital Signs  ................................................................................................. 38 
13.2.3 ECG
 Monitoring ....................................................................................... 
39 
13.2.4 Body Weight ............................................................................................. 39 
13.2.5 Clinical Laboratory Tests  .......................................................................... 39 
13.2.6 Adverse Events  ......................................................................................... 40
 
[IP_ADDRESS] Adverse Even
t Definition  ......................................................... 40 
[IP_ADDRESS] Monitoring ............................................................................... 40 
[IP_ADDRESS] Re
porting .................................................................................. 41 
[IP_ADDRESS] Serious Adverse Event ............................................................. 42 
13.3 Pharmacokinetic Assessments  ................................................................................. 43 
13.3.1 Blood Sampling and Pr
ocessing ............................................................... 43 
13.3.2 Future Analyses  ........................................................................................ 44 
13.3.3 Pharmacokinetic P
arameters  ..................................................................... 44 
13.3.4 Anal
ytical Method  .................................................................................... 45 
13.4 Blood Volume Drawn f
or Study Assessments ........................................................ 46 
14 STATISTICAL CONSIDERATIONS  .......................................................................... 47 
14.1 Sample Size Dete
rmination  ..................................................................................... 47 
14.2 Population for Analy
ses .......................................................................................... 47 
14.3 Statistical Analyses  ................................................................................................. 47 
14.3.1 Safety Analyses  ......................................................................................... 47
 
14.3.2 Pharmacokinetic A
nalyses  ........................................................................ 48 
[IP_ADDRESS] Descriptive Statis
tics ................................................................ [ADDRESS_1251004] Information and Consent.............................................................. 49 
15.1.4 Confidentiality  .......................................................................................... 49 
15.2 Termination of the
 Study ......................................................................................... 50 
15.3 Data Quality Assurance  ........................................................................................... 50 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
10
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251005] Access to
 Source Data/Documents  .............................................................. [ADDRESS_1251006] OF TABLES  
Tab
le 1: Ma
ximum concentration (Cmax) values following single dose 
LOXO -292 (160 mg) administ
ered under fasting conditions ........................ 23 
Table 2: Blood Volume during the Study .................................................................... 46 
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
11
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 10 5 SYNOPSIS  
Compound: LOXO -
292 
Clinical Indication: Cancer  
Study Phase and Type:  Phase 1  – Single ascending  dose (SAD), safety, and tolerability.  
Study Objective s: Primary:  
To assess the 
safety and tolerability of single oral doses of 
LOXO -292 when administered to healthy adult subjects. 
Secondary:  
To assess the pharmacokinetics (PK) of single oral doses of 
LOXO -292 when administered to healthy adult subjects. 
Summary of Study 
Design:  This is a P hase I, safety , tolerability, and PK SAD study.   
Up to [ADDRESS_1251007] 48 hours before the remaining 4 subjects . Blood 
samples will be collected for the PK assessment of LOXO -292 in 
plasma for 168 hours postdose. 
Safety and tolerability will be assessed through  End of Tr eatment 
(EOT ) or Early Termination ( ET) by [CONTACT_12902] 
(AEs), performing physical examinations, and clinical laboratory 
tests, measuring
 vital signs, and recording electrocardiograms 
(ECGs ).  
Dose escalation to a higher dose level (i.e., next cohort) will not 
take place until the PI [INVESTIGATOR_893271]/tolerability data (e.g., physical examinations, ECGs, vital 
signs, clinical laboratory tests, and AEs) through a minimum of 
48 hours ( Day 3) postdose for Cohort 1 and through a minimum of 
120 hours postdose (Day 5) for Cohort [ADDRESS_1251008] determined that 
adequate safety and tolerability from the previous, lower dose, 
cohort has been demonstrated to permit proceeding to the next 
cohort. Bioanalytical data, if available, may be used to guide the 
dose- escalation decision.  
The clini cal research unit (CRU)  will contact [CONTACT_893294] -292 (including subjects who terminate from the 
study early [ET] ) at the End of Study (EOS, as defined in the 
Study Events Flowchart, Section 6 ) by a follow up phone call 
(FU). The EOS/FU phone call will be performed  7 days (± 2 days) 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.[ADDRESS_1251009] s: 
Dosage, Dosage F01m , 
Route, and Dose 
Regimen: 
Dose 
Escalation/Stoppi[INVESTIGATOR_893272]27486 (LOXO -RET -[ZIP_CODE]), Final Proto col, 25Jan2019 
after EOT or ET ( as defined in the Study Events Flowchati , 
Section 6) to detennine if any serious adverse event (SAE) or 
study drng AE has occmTed since EOT or ET. 
Tue study is pl anned to emoll up to 18 health y, adult male and 
fema le ( of non-ch ildbea 1ing potential only) subjects (up to [ADDRESS_1251010] s in each coho 1t). Eve1y attempt will be 
made to emoll at least 1 fema le in each coho1i. 
Planned dose levels will be as follows: 
Coholi 1: 320 mg LOXO-292 (4 x 80 mg capsules) on 
Day 1 
Coh01i 2: '.S 640 mg LOXO-2 92 ('.S 8 x 80 mg capsules) on 
Dayl 
Coholi 3: '.S 720 mg ('.S 9 x 80 mg capsules) LOXO- 292 on 
(Opt ional) Day 1 
Additional cohorts ( 6 subjects per coho1t) may be emolled if it is 
deemed appropriate to repeat any dose level, or to add an interim 
dose level or levels (lower than 720 mg), as determined by [CONTACT_893295], dependin g on the safety and 
tolerabili ty results from the prior coh01i(s). Dosing will not exceed 
[ADDRESS_1251011]. 
The decision to proceed to the next higher dose administrat ion will 
be made following the review of all peliinent safety/tolerability 
data ( e.g., physical examinations , ECG s, vital signs, clinica l 
laborator y tests, and AEs) from a ll subjects through a minimum of 
48 hour s (Day 3) postdose for Coho1t 1 and through a minimum of 
120 hour s postdose (Day 5) for Coholi 2. Dose escalation to the 
next dose level (i.e., next coho1t) will not take place until the PI 
[INVESTIGATOR_893273]1mined that adequate safety and 
tolerabilit y from the previous, lower dose, coholi has been 
demonstrated to permit proceeding to the next cohort 
Together they will make one of the following determinat ions: 
1. To continue with the study as planned. 
Page 11 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protocol and Protocol Amendme nts 13 
CONFIDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
2. To continue with the study and add additiona l safety 
evaluat ions to subsequent coh01ts. 
3. fu the event of the following occunence: 
One (1) or more subject(s) at a given dose level exper iences a 
drng related Common Tenninology Criteria for Adverse 
Events (CTCAE) grade~ 3 toxicity, which is deemed 
clinically significant by [CONTACT_978] [INVESTIGATOR_893274] , a decision will be made as follows: 
• Continue with the study by [CONTACT_893296] ; 
• Adjust to an inte1med iate dose between the cmrent dose 
and the next planned dose ; 
• Adjust to an inte1mediate dose between the cmrent dose 
and the previous lower dose ; 
• Dose administration may be pe1mitted to continue as 
deemed by [CONTACT_976], in agreement with the Sponsor , where the 
safety parameter assessed does not pose a subject safety 
risk based on safety knowledge from prior LOXO -292 
studies. 
4. fu the event of the following occUITence: 
Two (2) or more subjects in a dose level experience a drng 
related CTCAE grade 3 toxicity , which are deemed clinically 
significant by [CONTACT_978] [INVESTIGATOR_893275], a decis ion will be made as follows: 
• Dose administration may be pe1mitted to continue as 
planned if deemed acceptable by [CONTACT_976], in agreement with the 
Sponsor , where the safety parameter assessed does not 
pose a subject safety risk based on safety know ledge from 
prior LOXO -292 studies ; 
• Evaluate an alternat ive dose level; 
• The study may be terminated with no additional dose 
administration to any subjects. 
5. One (1) or more subject(s) in a dose level has a drng related 
SAE , a decision will be made as follows: 
• Evaluate an alternat ive dose level; 
• The study will be terminated with no additiona l dose 
administration to any subjects in any coh01t. 
Bioanalytical data may be used , if available , to guide 
dose -escalation decisions or for selection of an alternate dose for 
evaluation , and/or to confum the sampling schedule. 
Page 12 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 14 
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 13 A sufficient period of time will be allowed  between Day 3 of 
Cohort 1 and the dose of the next cohort and  between  Day 5 of 
Cohor
t 2 and the dose of the next cohort in order for the PI [INVESTIGATOR_893276]. 
Key Assessments: Safety: 
All safety
 assessments, including AEs and SAEs, vital sign 
measurements, clinical laboratory results, physical examination 
results, concomitant medications, and ECG interpretations, will be 
tabulated and summarized where possible, using descriptive 
methodology by [CONTACT_12268].  
Pharmacokinetics:  
The following PK parameters will be calculated for LOXO-292 in 
plasma, as appropriate: AUC0 -t, AUC0 -24, AUC0-inf, 
AUC%extrap , CL/F, Cmax, Tmax, Kel , t½, and Vz/F. 
Future analysis in plasma for metabolite(s) formation  may be 
conducted. 
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
15
CONFIDENTIAL  CA2 7486 ( LOX O-RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 14 6 STUDY EVENTS FLO
W CHART  
Study Procedure a 
Scr b Study Days  
FU/ 
EOS e Days → -1 1 2 3 4 5 6 7  8 
Clinic Discharge/  
EOT or ET d 
Hours →  C-I c 0 0.25 0.5 0.75 1 1.5 2 2. 5 3 4 6 8 12 24 36 48 72 96 120 144 168 
Administrative Procedures                          
Informed Consent  X                        
Inclusion/Exclusion Criteria  X X                       
Medical History  X                        
Safety Evaluations                          
Full Physical Examination  f X                      X  
Abbreviated Physical 
Examination  f  X     X                  
Height  X                        
Weight  X X                      X  
12-Lead Safety ECG g X X              X    X   X  
Vital Signs (HR and BP ) h X X X i      X   X    X  X X X X X X  
Vital Signs (T)  X X X i                    X  
Hem, Serum Chem j, Coag, 
and UA  X X              X j    X   X  
Thyroid Stimulating 
Hormone  X                        
Hemoglobin A1c X                        
Serum Preg Test ( ♀ only)  X X                     X  
Serum FSH (PMP ♀ only)  X                        
Urine Drug Screen  X X                       
Urine Alcohol Screen  X X                       
Urine Cotinine  X X                       
HIV/Hepatitis Screen  X                        
AE Monitoring k X X 
ConMeds Monitoring  X X 
Study Drug Administration 
/ PK                          
LOXO -292 Administration    X                      
Blood for LOXO -292 l   X  m X X X X X X X X X X X X X X X X X X X X  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
16
CONFIDENTIAL  CA2 7486 ( LOX O-RET -[ZIP_CODE]), Final Protocol, [ADDRESS_1251012]
udy Days  
FU/ 
EOS e Days → -1 1 2 3 4 5 6 7 8
 
Clinic Discharge/  
EOT or ET d 
Hours →  C-I c 0 0.25 0.5 0.75 1 1.5 2 2.5 3 4 6 8 12 24 36 48 72 96 120 144 168 
Other Procedures                          
Confinement in the CRU  n  X  
Visit  X                        
 
Footnotes:  
a: For details o
n Procedures, refer to Section  13. 
b: Within 28 days prior t
o LOXO -292 administration.  
c: Subjects will be admitted to the CRU  at C-I (Day -1), at the time indicated by [CONTACT_47365].  
d: To be performed at EOT or at ET.  EOT is def ined as when the subject is released  from the CRU following completion of all assessments throug h Day [ADDRESS_1251013]  release from the CRU at EOT or ET. 
e:  To be performed 7 days (± 2 days) following EOT or ET. End of Study ( EOS) is defined as when t he CRU contacts the subject by [CONTACT_25600] 7 days  (± 2 days)  after EOT or 
ET to determine if any  SAE or  study drug related AE has occurred since EOT or ET . All subjects who received LOXO -292 (including subjects who terminate the study 
early) will be contact[INVESTIGATOR_530].  
f: Symptom-driven physical examination(s) may be performed  at other times, at the PI’s or designee’s discretion. Scheduled abbreviated physical examination s will include, 
at a minimum, examination of respi[INVESTIGATOR_696], cardiovascular, and gastrointestinal systems, with the option for further examination of additional systems as necessary based on 
reported symptoms/AEs.  
g: Subjects are to be supi[INVESTIGATOR_1919] 10 minutes prior to ECG assessment . ECGs will be obtained prior to and as close as possible to the scheduled blood draws  if scheduled 
at the same time. 
h:  Vital signs (HR and BP) will be obtained at Screening , C-I (Day -1), predose, and at 2 hours (± 10 minutes) and 4 hours (± 10 minutes) postdose  on Day 1 , and once daily 
through EOT (or ET). Vital sign measurements should be carried out prior to and as close as possible to having blood drawn. BP and HR will be measured using the same 
arm for each reading .  Subjects are to be supi[INVESTIGATOR_156164] t 5 minutes prior to vital signs assessment s.  
i: To be performed within 2  hours prior to dosing  on Day 1.  
j: Samples for serum chemistry will be obtained following a fast of at least 12 hours at Screening and at C-I (Day -1); at other scheduled times, serum chemistry tests will be 
performed after at least an [ADDRESS_1251014]  be obtained under fasting conditions.  
k: AEs and SAEs will be recorded beginning at informed consent. AEs will be recorded throughout the study (i.e., from signing of the ICF until EOS or ET if the subject 
discontinues from the study and does not complete a follow up call ), either as subject medical history (if the event is reported as beginning prior to signing of the ICF or if 
the event occurs prior to study drug administration on Day 1 and is assessed as not related to study procedures by [CONTACT_978] [or designee] ) or as AEs (if the event occurs after 
signing of the ICF but prior to study drug administration on Day 1 and is assessed as related to study procedures  by [CONTACT_978] [or designee] , or if the event occurs after study 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
17I 
CONFIDENTIAL  CA2 7486 ( LOX O-RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 16 drug administrat
ion on Day 1 through EOT  or ET regardless of relationship to study drug ). From EOT  or ET through EOS  only AEs assessed  as related to study drug by 
[CONTACT_978] (or designee)  are to  be reported.  All SAEs  that develop from the time of ICF signing until EOS (or ET, if the subject discontinues from the study  and does not 
complete a follow up call) are to be reported.  
l:  The sampling window s for PK blood samples will be as follows: within 30 minutes prior to dosing for the predose sample time  point; ± [ADDRESS_1251015] 12  hours; ±  30 minutes for sampling time  points > 12 hours ≤  36 hours; and ±  60 minutes for the sampling time  points from ≥ 48 to ≤ 168 hours .  
m: To be performed prior to dosing.  
n: Subjects will be confined to the CRU until the completion of 168- hour blood draw  and EOT procedures or until completion of ET procedures . 
 
Abbreviations: ♀ = Females,  AE = Adverse events, BP  = Blood pressure, C -I = Check -in, Chem  = Chemistry, Coag = coagulation, ConMeds  = Concomitant medication, 
CRU = Clinical research unit, ECG  = Electrocardiogram,  EOS = End  of Study,  EOT  = End of Treatment, ET = Early termination , FSH = Follicle -stimulating hormone, 
FU = Follow  up, Hem  = Hematology, HIV  = Human immunodeficiency virus, HR  = Heart rate, ICF= Informed consent form, PI = Principal Investigator, PMP  = Postmenopausal, 
Preg = Pregnancy , PK = Pharmacokinetic, SAE = Serious adverse event, Scr  = Screening, T  = Temperature, UA  = Urinalysis.   
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
18
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251016]  Aspartate aminotransferase 
AUC0 -24 The area under the concentration -time curve, from time 0 to 
Hour 24 
AUC%extrap  Percent of AUC0 -inf extrapolated  
AUC0 -t Area under the concentration -time curve, from time  [ADDRESS_1251017] 
observed non-zero concentration (t) 
AUC0 -inf Area under the concentration- time curve , from time  0 
extrapolated to infinity  
AV Atrioventricular  
BP Blood pressure 
BID Twice daily  
bpm Beats per minute  
BMI  Body mass index 
CFR  Code of Federal Regulations  
CL/F  Apparent total plasma clearance after oral (extravascular) 
administration  
Cmax  Maximum observed concentration  
CRF  Case report form  
CRU  Clinical Research Unit  
CTCAE  Common Terminology Criteria for Adverse Events 
CYP  Cytochrome P450 
ECG  Electrocardiogram  
EOS  End of Study 
EOT  End of T reatment  
ET Early T ermination  
FDA  Food and Drug Administration 
FSH Follicle -stimulating hormone  
FU Follow up 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
19
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 18 g gram  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice 
HBsAg  Hepatitis B surface antigen  
HCV Hepatitis C virus  
hERG  Human ether -a-go-go related gene  
HIV Human immunodeficiency virus 
HRT  Hormone replacement therapy  
IB Investigator’s Brochure 
IC50 Inhibitory concentration at 50% 
ICF Informed Consent Form 
ICH International Council  on Harmoniz ation  
IND Investigational New Drug  
IRB Institutional Review Board  
IUD Intrauterine device  
Kel Apparent terminal elimination rate constant  
kg Kilogram  
LFT Liver function test 
m2 Meter squared  
MedDRA® Medical Dictionary for Regulatory Activities® 
mg Milligram  
mL Milliliter  
mmHg  Millimeter of mercury  
msec Millisecond  
NCI National Cancer Institute  
ng Nanogram  
No. Number 
PCR  Polymerase chain reaction  
PI [INVESTIGATOR_12453](s)  
QA Quality Assurance 
QTc Corrected value of the interval between the Q and T  waves on the 
electrocardiogram tracing  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
20
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 19 RBC  Red blood cell 
RET Rearranged during transfection  
RSI Reference Safety Information  
SAD Single ascending dose 
SAE  Serious adverse event  
SAP Statistical analysis plan  
S[LOCATION_003]R  Suspected unexpected se rious adverse reaction  
TEAE Treatment -emergent adverse events   
Tmax  Time to reach maximum observed concentration  
t½ Apparent terminal elimination half -life 
US [LOCATION_002]  
[LOCATION_003] [LOCATION_002] of America  
Vz/F  Apparent volume of distribution during the terminal elimination 
phase after oral (extravascular) administration  
WBC  White blood cell 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
21
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 20 8 INTRODUCTION 
8.1 Back
ground 
8.1.1 LOXO -292 
LOXO -292 is small molecule and a selective inhibitor of the rearranged during transfection 
(RET) receptor tyrosine kinase designed to competitively block the adenosine triphosphate 
binding site of the kinase. LOXO-[ADDRESS_1251018] 250-fold more selective for RET than for 
98% of [ADDRESS_1251019] human cancer cell lines without RET alterations. Poten t and selective inhibition of 
RET may provide clinical benefit to subjects with malignancies due to oncogenic alterations 
in RET or with other mechanisms of increased RET activity. 
Nonclinical  
Cardiac safety of LOXO -292 was evaluated in a Good Laboratory Practice ( GLP ) in vitro 
assay for human ether-a- go-go related gene (hERG) activity, in a GLP in vivo study in 
conscious telemetry -instrumented minipi[INVESTIGATOR_14107], and in a GLP 28- day repeat -dose toxicology 
study (with ECG monitoring) in minipi[INVESTIGATOR_14107]. LOXO-292 had a 50% inhibitory concentration 
(IC50) value of 1.1 μM in the GLP hERG assay, which is approximately 14- and 6-fold higher 
than the predicted maxim um unbound concentration at the dose of 80 mg and 160 mg 
respectively twice daily ( BID). There were no LOXO-292- related changes in any 
cardiovascular endpoints including QT interval corrected for heart rate ( QTc) at doses up to 
12 mg/kg in the safety pharmacology cardiovascular study in conscious minipi[INVESTIGATOR_14107]. 
Furthermore, there were no LOXO-292- related ECG changes in the 2 8-day repeat -dose 
toxicity study in minipi[INVESTIGATOR_42423] 12 mg/kg. Together, these data indicate that 
LOXO -292 has a low risk of inducing delayed ventricular repolarization, prolongation of the 
QTc interval, and unstable arrhythmias. 
Administration  of LOXO -292 at single doses up to 45 mg/kg in male rats had no effect on 
respi[INVESTIGATOR_4806]. 
Potential effects of LOXO -292 on the central nervous system were evaluated as part of the 
GLP  28-day repeat -dose study in rat s, in functional observational battery tests and locomotor 
activity assessments. Findings were limited to animals receiving the high dose on week  4 of 
the dosing phase, and were attributed to poor general body condition and weight changes 
associated with LOXO -292 administration rather than specific neurological effects. 
Additionally, no microscopic abnormalities in neuronal tissues were found. 
In toxicology studies of LOXO-292 that were conducted in the rat and minipig, the primary 
pathologic findings for both species were in the tongue, pancreas, bone marrow and 
lymphoid tissues; while the gastrointestinal tract and ovaries were target tissues in minipig. 
Other target tissues identified in the rat included: multi- tissue mineralization, physeal 
cartilage, incisor teeth, lung, Brunner’s gland, and possibly liver. Assessment of doses 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
22
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 21 associated with m
oribundity/death revealed a steep dose response curve for both species. 
LOXO -292 was not mutagenic in the GLP bacterial mutation assay. When evaluated in two 
in vitro assays, LOXO-292 was not genotoxic.  LOXO-292 was not found to be phototoxic 
when evaluated in an in vitro neutral red uptake phototoxicity assay. 
Based on preclinical pharmacology experiments with human cancer cells in vitro and in 
murine xenograft models, meaningful inhibition of RET in tumors is expected to be 
achievable with oral dosing regimens ≥ 40 mg/day. 
Based on the nonclinical profile, including results from animal toxicology studies, theoretical 
risks of human exposure to LOXO-292 include the following: loss of appetite, decrea se in 
body weight, increase in total white blood cells, neutrophils, and monocytes, decrease in 
albumin, increase in globulin, decreased albumin:globulin ratio, decrease in total protein, 
increased body temperature, lethargy, increase in cholesterol and triglycerides, increase in 
phosphorus, changes in taste sensation and/or development of xerostomia, gastrointestinal 
symptoms/signs: nausea, vomiting, loose stools, abdominal discomfort, decreases in red cell 
mass ( red blood cell [RBC] , hemoglobin, hematocri t) and reticulocytes, decrease in platelets, 
increases in liver function tests (alkaline phosphatase, aspartate aminotransferase, and alanine 
aminotransferase)  and possible pancreas injury. 
LOXO -[ADDRESS_1251020] that the pharmacokinetic exposure of LOXO-292 may 
be reduced by [CONTACT_42471]. LOXO-292 appears to be 
metabolized primarily by [CONTACT_9058] p450 ( CYP )3A4, but at therapeutically relevant 
exposures, it is not anticipated to inhibit or induce drug- metabolizing enzymes. LOXO -292 is 
also a substrate for BCRP . 
Refer to the Investigator’s Brochure (IB)  for detailed background information on LOXO-292 
(Investigator’s Brochure, Version 4, October 2018 ). 
Clinical  
LOXO -292 is currentl
y being studied in an ongoing global Phase 1/2  (Study LOXO -
RET-[ZIP_CODE]) in patients with advanced solid tumors including RET  fusion-positive NSCLC, 
RET-mutant medullary thyroid carcinoma , and other tumors with increased RET activity. 
The starting dose of LOXO-[ADDRESS_1251021] dose administered. As of this date, two dose- limiting toxicities 
(DLTs) of tumor lysis syndrome and Grade [ADDRESS_1251022] frequently reported t reatment -emergent adverse events 
(TEAEs ; [> 10% of patients]), were dry mouth (20.3%; 14.4% related), diarrhea (15.7%; 
7.2% related), fatigue (15.7%; 11.8% related), constipation (12.4%; 2.6% related), headache 
(11.1%; 3.3% related), and hypertension (10.5%; 3.9% related). Regarding TEAEs , 8 patients 
experienced ≥ Grade 3 TEAEs that were judged by [CONTACT_331590]. 
Three (3) patients  have died within [ADDRESS_1251023] dose of study drug and no deaths 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
23
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251024] ( LFT) abnormalities, considered related to the study drug, occurring 
between [ADDRESS_1251025] 24 2018, PK data were available from 141 patients (from the global Phase 1/2 
study). LOXO-292 is absorbed after oral administration with a median time to maximum 
concentration (Tmax) of approximately 2 hours. Although the PK sampling of LOXO-292 
was not long enough to adequately characterize AUC0-inf, the half- life appears to be 
20 hours. Low concentrations of LOXO-292 were recovered as unchanged drug in urine 
indicating that the kidney contributes to overall clearance. 
As of September 14, 2018, Loxo Oncology has initiated 16 single patient protocols, Special 
Access Scheme, or Temporary Authorization Use cases to provide access to LOXO -292 for 
patients  with clinical need not meeting eligibility criteria for the ongoing global Phase 1/[ADDRESS_1251026] been attributed to study drug for these patients. 
Preliminary PK data available from ongoing studies (LOXO -RET-[ZIP_CODE] and 
LOXO -RET-[ZIP_CODE]) bei ng conducted in healthy subjects indicate that LOXO -[ADDRESS_1251027] been preliminarily determined. LOXO -RET-[ZIP_CODE] is  a drug -drug 
interaction study evaluating the effects of itraconazole and rifamp in on the PK of 
LOXO -292. In LOXO- RET-[ZIP_CODE] the effects of food and of a proton-pump inhibitor 
(omeprazole)  are being  evaluated on the PK of LOXO-292. Preliminary Cmax data was 
reported  for LOX O-292 following each study part and data when LOXO -292 was 
administered alone under fasted conditions in these studies are presented in Table 1 (Data on 
file at the time of p
rotocol dev elopment).  
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
24
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 23 Table 1: Maximum 
concentration (Cmax) values following s ingle dose LOXO -292 
(160 mg) administered under fasting conditions  
LOXO -292 Study Number  Part  Sample Size (n)  Cmax* ( ng/mL) 
LOXO -RET-[ZIP_CODE] 1 12 1656 ± 626 ng/mL  
LOXO -RET-[ZIP_CODE] 2 12 1458 ± 626 ng/mL  
LOXO -RET-[ZIP_CODE] 1 20 2223 ± 685 ng/mL  
*Arithmetic mean (AM) ± standard deviation (SD)  
Cmax = Maximum concen
tration  (preliminary data), mL  = milliliter, ng  = nanogram  
   
Single doses of great
er than [ADDRESS_1251028] the s ingle -dose Cmax average value following dose level of 160 mg 
LOXO -292 is approximately 1800 ng/mL.   
In a dose- exposure analysis in cancer patients who received doses of 20 mg once daily  to 
240 mg BID  in the ongoing Phase 1/2 LOXO- RET -[ZIP_CODE] Study, the CL/F  of LOXO-292 
decreased with increasing dose strength  leading  to greater than proportional increases in 
LOXO -292 exposure with increases in LOXO-292 doses. The steady -state Cmax of  
LOXO -292 in cancer patients treated with 160 mg BID, the currently recommended Phase 2 
dose and dos e planned for commercialization,  is 3320 ± 1220 ng/mL (n=65, Investigator’s 
Brochure, Version 4, Octobe
r 2018).  Based on the data from a single dose of 160 mg when 
administered to healthy subjects , the Cmax of a single dose of 320 mg ( the dose selected for 
Cohort 1) is expected to be twice as high as from 160 mg i.e., approximately 3600 ng/mL, 
representing  the therapeutic Cmax value expected in patients . The dose of 640 mg was 
selected for Cohor t 2 as  with linear PK, it is anticipated  to produce a Cmax of approximately 
6640 ng/mL, which is approximately twice as high as the Cmax seen in cancer patients 
treated with 160 mg BID LOXO-292 and would be considered the supratherapeutic exposure 
target.  
All AEs reported following LOXO-292 administration in LOXO- RET-[ZIP_CODE] were ≤ Grade 2 
in severity and not considered related to LOXO -292. The majority of AEs reported in 
LOXO -RET-[ZIP_CODE] were ≤ Gra de 2 in severity. There was one Grade 3 event of 
hypertriglyceridemia reported during the study  and considered treatment related . Other 
LOXO -292 related events in this study  included Grade 1 increased alkaline phosphatase 
(ALP) , Grade 2 increased serum amylase, Grade 1 increased alanine aminotransferase 
(ALT ), Grade 1 increased aspartate aminotransferase (AST), and Grade 1 dyspepsia (Data on 
file at the time of protocol development) .     
8.2.3 Rationale for Primary Endpoints  
The primary endpoint of this study is to assess the safety  and tolerability  of LOXO -292. 
LOXO -292 has already been administered to healthy subjects (LOXO -RET-[ZIP_CODE] and 
LOXO -RET-[ZIP_CODE]) at a single dose level of 160 mg. As a dose- exposure analysis in cancer 
patients  (LOXO- RET -[ZIP_CODE]) indicated that a reduction in clearance led to greater than 
proportional increases in LOXO-292 exposure with increases in LOXO-292 doses, this study 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
25
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 24 will investigate the
 safety and tolerability of higher doses  (i.e., potential therapeutic and 
supratherapeutic doses)  of LOXO-[ADDRESS_1251029] any safety signals when these higher doses  of 
LOXO -292 are administe red to healthy subjects .   
8.3 Risks and/or Benefits to Subjects  
The doses of LOXO -292 administered in this study are not anticipated to induce any 
significant risk or benefit to subjects participating in this study . The  dose escalation 
procedures and safety monitoring practices employed by [CONTACT_3181] (i.e., 12- lead ECG, 
vital signs, clinical laboratory tests, AE  monitoring , and physical examination) are adequate 
to protect the subjects’ safety.  
There will be no direct health benefit for study participants from receipt of study drug. An 
indirect health benefit to the healthy subjects enrolled in this study is the free medical tests 
received at S creening and during the study.
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
26
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 25 9 OBJECTIVE S AND ENDPO
INTS 
9.1 Objectives 
Primary : 
To assess the safety and tolerability of single oral doses of LOXO -292 when administered to 
healthy adult subjects . 
Secondary:  
To assess the PK of single oral doses of LOXO-292 when administered to healthy adult 
subjects . 
9.2 Endpoint s 
Safety: 
Safety endpoints will include AEs including the subject incidence, number, and severity of 
TEAEs followin g single oral doses of LOXO-292 in healthy adult subjects and safety markers 
for 12-lead ECGs, physical examinations, vital signs, and clinical laboratory tests.  
Pharmacokinetics:  
The plasma PK endpoints will include AUC0 -t, AUC0 -24, AUC0-inf, AUC%extrap, CL/F, 
Cmax, Tmax, Kel, t½, and Vz/F. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
27
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 26 10 STUDY DESIGN  
10.1 Over
all Study Design and Plan 
This is a Phase I, safety , tolerability, and PK SAD study.   
Screening of subjects will occur within 28 days prior to dosing. 
The study is planned to enrol up to 18 healthy, adult male and female (of non -childbearing 
potential only) subjects. Every  attempt will be made to enrol at least [ADDRESS_1251030] 48 hours before the remaining 
4 subjects. Blood samples will be collected for the PK assessment of LOXO -292 in plasma for 
168 hours postdose. 
Safety and tolerability will be assessed through EOT or ET by [CONTACT_42466], performing 
physical examinations, and clinical laboratory tests, measuring vital signs, and recording 
ECGs.  
Dose escalation to a higher dose level (i.e., next cohort) will not take place until the PI [INVESTIGATOR_893277]/tolerability data (e.g., physical examinations, ECGs, 
vital signs, clinical laboratory tests, and AEs) through a minimum of 48 hours ( Day 3) postdose 
for Cohort 1 and through a minimum of 120 hours postdose (Day 5) for Cohort [ADDRESS_1251031] 
determined that adequate safety and tolerability from the previous, lower dose, cohort has been 
demonstrated to permit proceeding to the next cohort . Bioanalytical data, if available, may be 
used to guide the dose- escalation decision.  
Timing of all study procedures are indicated in the Study Events Flow Chart ( Section  6). 
Subjects may be re
placed at the discretion of the Sponsor. 
10.1.1 Confinement , Return Visits , and Follow- Up 
Subjects will be housed in the CRU through EOT or ET beginning on Day -1, at the time 
indicated by [CONTACT_47365], until after completion of study procedures on Day 8 (EOT)  or ET  study 
procedures. EOT is defined as the day on which the subject is released from the CRU, 
following all study procedures (see Study Events Flow Chart, Section  6). Vital signs, ECG, 
clinical safety labo
ratory results , and AEs  are to be available for review by [CONTACT_978] [INVESTIGATOR_893278] r elease from the CRU  at EOT or ET. At all times, a subject may be required to remain 
at the CRU for longer at the discretion of the PI [INVESTIGATOR_50286]/or Sponsor.  
The CRU will contact [CONTACT_893297] -292 (including subjects who terminate 
from the study early  [ET] ) at the E OS (as defined in the Study Events Flowchart, Section 6 ) 
by a follow up phone call (FU)
. The EOS/FU phone call will be performed 7 days (± 2 days) 
after EOT or ET (as defined in the Study Events Flowchart, Section 6 ) to determine if any SAE 
or study drug relat e
d AE has occurred since EOT or ET. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
28
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 27 10.1.2 End of Study De
finition 
End of Study (EOS) is defined as the day on which the subject completes the follow up phone 
call (Study Events Flow Chart, Section 6 ). 
 
Study completion applies
 to the clinical conduct of the study overall (i.e., last subject’s 
Follow-up phone call). 
  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
29
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
[ADDRESS_1251032] fulfill all of the follow ing inclusion criteria to be eligible for participation in the 
study: 
1. Healthy, adult, male or fema le ( of non-childbearing potent ial only), 18-5 5 years of age, 
inclusive, at Scree ning. 
2. Contin uous non-smok er who has not used tobacco -and/or nicot ine-conta ining products for 
at least 3 months prior to dosing and through EOT or ET. 
3. Body mass index (BMD 18.0 and:=:; 32.0 kg/m2 at Scree ning and have a minimum weight 
of at least 50 kg at Screening. 
4. Medica lly healthy with no clinically signi ficant medical histo1y , physi cal examination , 
laboratory profiles, vital signs or ECGs , as deemed by [CONTACT_978] [INVESTIGATOR_1461], and as confirmed 
by [CONTACT_1034]. Live r function tests (ALT and AST), semm (tota l and direct) bilimbin, 
amylase and lipase , and tests for hemoglob in, white blood cells (WBCs) , and neutrophi ls 
must be within the u pper limit of n01mal for the laborat01y used by [CONTACT_893298] -in (D ay-I). Rechecks of the liver function tests (ALT and AST) , 
sernm (tota l and direct) bilirnbin , amylase and lipase , and tests for hemoglobin, WBCs , and 
neutrophi ls wi ll be permitted up to two times to confnm su bject eligibility. Subjects may be 
eligible for paiticipatio n in the study based on rechecked values if the PI (or designee) , 
with agreement from the Sponsor , feels that the results are not clinically significant, and 
will not impact study cond uct. 
5. A fema le of non-childbearing potent ial: must have undergone one of the following 
sterilization procedures at least 6 months prior to dosing: 
• hysteroscop ic sterilization ; 
• bilateral tubal ligation or bilateral salpi[INVESTIGATOR_42451]; 
• hysterecto my; 
• bilateral oophorectomy; 
or be postmenopa usal with amenoIThea for at least I yeai· prior to dosing and 
follicle-stimu lating ho1mone (FSH) semm levels cons istent with postmenopausa l status . 
6. Males who are capab le of fathering a child must agree to use one of the following metho ds 
of contracept ion from the time of the dose admin istration through [ADDRESS_1251033] 
dose: 
Page 28 
LOXO -RET -1805 7; CA27 486; 16.1.1 Protocol and Protocol Amendments 30 
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
Male subjects will be surgically sterile for at least 90 days prior to Chec k-in (Day -1). If 
documentat ion is not available, male subjects must follow the contracept ion methods 
below: 
a. Male condom with spermicide, and 
b. For a female partner of male s tudy participant: 
l .Intrnuterine device (IUD) (ho1monal IUD ; e.g., Mirena®). Copper IUDs 
are acceptab le (e.g., ParaGard®) ; 
2.Established use of oral, implanted, transde1 mal, or hmmonal metho d of 
contracept ion assoc iated with inhibition of ovulation; or 
3.Bilateral tubal ligation. 
Males who pract ice tru e abstinence because of a lifesty le choi ce (i.e., do not become 
abstinent just for the purpose of study pa1 t icipation) are exempt from contracept ive 
requiremen ts. Periodic abstine nce by a fema le partner (e.g., calendar, ovulation, 
symptothe1 m al, postovu lation methods) and withdrawa l are not accepta ble methods of 
contracept ion. If a male su bject is ab stinent at the time of signing the info1me d consent 
fo1m (ICF) but b ecomes sexually active during the study , he must agree to use 
contracept ion as descr ibed above. 
Male subjects should ens ure that condoms with spe1micide are used from the time of the 
study drng admi nistr·ation until [ADDRESS_1251034] feeding. Male subjects are 
required to refrain from donation of spe1m from Check -in (Day -1) until [ADDRESS_1251035] not be emolled in the study if they meet any of the following criteria: 
1. Is mentally or legally incapac itated or has significant emot ional prob lems at the time of the 
Scree ning visit or expected dming the conduct of the study. 
2. History or presence of clinica lly significant medical or psyc hiatr·ic cond ition or disease in 
the opi[INVESTIGATOR_164976] , and as confirmed by [CONTACT_1034]. 
Page 29 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 31 
CONFIDENTIAL CA27486 (LOXO-RET-1 8057), Final Proto col, 25Jan2019 
3. History of any illness that, in the opi[INVESTIGATOR_164976], and as confnmed by [CONTACT_429] , might confound the results of the study or poses an additi onal risk to the subject 
by [CONTACT_893299]1ti cipation in the study. 
4. History of gastritis, gastrointe stinal tract, or hepati c disorder or other clini cal condition that 
might , in the opi[INVESTIGATOR_164976] , and as confnmed by [CONTACT_1034] , affect the 
absorption , distributi on, biotran sform ation, or excret ion of LOXO- 292. 
5. History or presence of alcoholi sm or drng abu se within the past 2 years prior to dosing. 
6. History or presence of hypersensitivity or idiosyncrat ic reaction to the study dmgs or 
related compounds, or inactive ingredient s. 
7. History or presence of: 
• liver disease, 
• pancreatitis, 
• pepti c ulcer disease , 
• intestinal malab sorption , 
• gastric reduction surger y, 
• history or presence of clinicall y signifi cant cardiovasc ular disease : 
o m yoca rdial infar ction or cerebrovascu lar thromboemboli sm within 6 month s prior 
to dosing 
o sympto matic angina pectolis 
o [LOCATION_001] Heart Association Class ~2 congestive heart failure 
o congenital prolonged QT syndrome 
o ventricul ar pre-excitation syndrome (Wolff-Parkin son White synd rome) 
o anhythmia or history of anhythm ia requirin g medi cal intervent ion 
o ventricular dysfunction or risk factors for Torsades de Pointe s (e.g., hea1t failure, 
cardio myopathy, family history of Long QT Syndrome) 
o s ignifi cant scree ning ECG abnorm alities: 
left bundle-bran ch bl ock 
second degree atrioventricu lar (AV) block, type 2, or third-de gree AV block 
Frederi ca conected QTc (QTcF) interval is >450 msec 
ECG :findin gs deemed abnormal with clinical signifi cance by [CONTACT_978] [INVESTIGATOR_893279]. 
8. Female subjects of childbearing potential. 
9. Female subjects w ith a positive pregnan cy test or who ar·e lactating. 
Page 30 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16. 1.1 Protocol and Protocol Amendments 32 
CONFIDENTIAL CA27486 (LOXO-RET-1 8057), Final Proto col, 25Jan20 19 
10. Positive urine chug or alcohol results at Screening or Check-in (Day-1). 
11. Positive urine cotinine test at Screening or Check-in (Day-1). 
12. Positive results at Screening for human immunodefi ciency vims (HIV) , hepatiti s B s urface 
antigen (HBsAg) or hepatiti s C v ims (HCV). Subjects who are positive for hepatiti s B 
vims , HCV , or HIV by [CONTACT_893300] 
(PCR ) before emollment to detect presence of active vims. Subjects who are PCR positive 
will not be eligible. 
13. Subjects w ith at-rest (i.e., supi[INVESTIGATOR_1919] 5 minute s) diastolic BP of <50 or >89 mmHg 
and/or supi[INVESTIGATOR_893280] <89 or >139 mmHg at Screening , Check-in (Day-1), and prior 
to dosing. Recheck s of blood pressure values will be permitted up to two times to confirm 
eligibility for study pa1ticipation. Subject s may be eligible for participation in the s tudy 
based on reche cked values if the PI (or designee) , with agreement from the Sponsor, feels 
that the results are not clinically significant , and will not impact study conduct. 
14. Supi[INVESTIGATOR_893281] 45 bpm or higher than 99 bpm at Screening , Check-in 
(Day -1 ), and prior to dosing. Recheck s of heart rate values will be permitted up to two 
times to confirm eligibility for study pa1ticipation . Subjects may be eligible for 
participation in the s tudy based on rechecked values if the PI ( or designee ), with agreement 
from the Sponsor , feels that the results are not clinically signifi cant, and will not impact 
study conduct. 
15. Estimated creatinine clearance <90 mL/min at Screenin g or Check-in (Day-1). 
16. Unable to refrain from or anticipates the use of any dmg , including prescription and 
non-prescription medi cations, herbal remedies , or natural or vitamin supplement s for 
14 days prior to dosing and throu gh EOT or ET, unless allowed by [CONTACT_978] (or designee), 
with agreement from the Sponsor. Hormone replacement therap y (HR T) is not permitted . 
After dosing, acetaininophen (up to 2 g per 24 hour s) may be admini stered at the discretion 
of the PI [INVESTIGATOR_1461]. 
17. Unab le to refrain from or anticipates the use of any inhibitor or inducer of CYP3A4 / AS or 
of P-gp for 28 days prior to dosing and through EOT or ET. Appropriate sources (e.g., 
Flockha1t Tabl e™) will be consulted to confirm lack of PK intera ction with study chug. 
18. Unab le to refrain from or anticipate s the use of proton pump inhibitor s, antacids and 
H2-receptor antagonists for 14 days prior to dosing and through EOT or ET. 
19. Unab le to refrain from or anticipates the use of any dmg s that prolongs the QT/QTc 
interval for 14 days prior to dosing and through EOT or ET. 
20. Has been on a diet incompatible with the on-study diet, in the opi[INVESTIGATOR_164976], 
and as confirmed by [CONTACT_1034], within the 30 days prior to dosing and through EOT or 
ET. 
21. Donation of blood or signifi cant blood loss within 56 days p1ior to dosing. 
Page 31 
LOXO-RET- 1805 7; CA27486 ; 16.1.1 Protocol and Protocol Amendme nts 33 
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
22. Plasma donation within [ADDRESS_1251036] igatio nal tr ial with LOXO -292. 
25. StTenuous exercise within 5 days prior to Check -in (Day -1). 
26. Dosing in any other investigational study drng trial involving administration of any 
investigat ional drng in the past 30 days or 5 half-lives (if known), whichever is longer, 
prior to dosing. 
11.[ADDRESS_1251037] s from the Study 
Subjects are free to withdra w from the study at any time for any reason. 
In addition , subjects may be withdrawn from the study by [CONTACT_978] [INVESTIGATOR_893282]: 
• AEs. 
• D ifficulties in blood collection. 
• P ositive pregna ncy test. 
• P ositive urine chug and alcoho l test. 
A subject may be withch·aw n by [CONTACT_978], d esignee , or the Sponsor if either consid ers emo llment 
of the subject into the study is inappropr iate, the study pl an is viol ated, or for administrat ive 
and/or other safety reasons. Prompt notification to the Sponso r of withch·awa l of any subject 
should be prov ided. 
Subjects who withch·aw from the study will undergo early termination from the study 
procedures as outlined in the Study Events Flow Chaii (Section 6). 
11.4 Study Restrictions 
11.4.1 Prohibition s and Concomitant Medication 
Cons umption of foods and beverages conta ining the following substances will be prohib ited as 
indicated: 
• Xanthi nes/Caffe ine: 24 hours prior to dosing and through EOT or ET (small amounts of 
caffe ine derived from n01ma l foodstuffs e.g., 250 mL/8 oz.fl cup decaffe inated coffee 
or other decaffeinated beverage, per day, with the except ion of espresso ; 45 g/1.[ADDRESS_1251038] ion); 
• Al cohol: 48 hours prior to dosing and through EOT or ET; 
• Grapefrn it/Seville orange and their juices: 14 days prior to dosing and through EOT or 
ET; 
Page 32 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 34 
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
• O ther Frnit Juice: 72 hours prior to dosing and through EOT or ET; 
Participation in any other in vestigational study drug ti-ial in which receipt of any in vestigationa l 
drng occurs within 5 half-lives (if known) or 30 days , whichever is longer, prior to dose 
administration (D ay 1) is prohibited. 
Any prescription or over-the-counter medications (including herbal prod ucts, natura l or 
vitamin supplements) will be prohi bited for at least 14 days prior to dosing through EOT or 
ET, unless allowed by [CONTACT_978] (or designee), with agree ment from the Sponso r, as descr ibed 
below. 
Any prescription or non-prescri ption medications that are inhibitors or inducers of CYP3A4 
and CYP3A5 or of P- gp will be prohibited for at least 28 days p1ior to dosing through EOT or 
ET. 
Any proton pump inhibitors, H2-receptor antagonists or antac ids will be prohibited for 14 days 
prior to dosing and through EOT or ET. 
Any mugs that prolong the QT/ QTc inte1val will be prohib ited for [ADDRESS_1251039] be discussed with the PI (or designee) , and/or Sponsor prior to 
use, unless approp riate medical care necessitates that therapy shou ld begin before the PI ( or 
designee) and/or Sponso r can be cons ulted. HRT is not pennitted. Following study mug 
adinin istration on Day 1, aceta minophen (up to 2 g per 24 hours) may be admi nistered at the 
discret ion of the PI (or designee). 
If deviations occur , the PI [INVESTIGATOR_893283] 
a case-by-case basis whether the subject may contin ue pa1ticipation in the study. 
All medicat ions taken (incl uding vitamins and supp lements) by [CONTACT_893301]. 
11.4. [ADDRESS_1251040] be obtai ned under fasting condit ions (i .e., p1ior to the sched uled standard 
breakfast). 
Each meal and/or snacks se1ved at the CRU will be standardized and will be similar in calor ic 
content and composition and w ill be taken at approxi mately the same time in each period. 
Page 33 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 35 
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251041] sports at any time from 5 days prior to Che ck-in 
(Day  -1) until EOT or ET. 
Subjects will not be permitted to smoke or ingest tobacco or nicotine containing products from 
3 months prior to Screening through the EOT or ET. 
  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
36
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251042] from food (not including water) for at 
least 4 hour postdose. 
Planned dose levels will be as f ollows: 
Cohort 1: 320 mg LOXO -292  (4 x 80 mg capsules) on Day 1 
Cohort 2: ≤ 640 mg LOXO -292 (≤ 8 x 80 mg capsules)  on Day 1 
Cohort 3: 
(Optional) ≤ 720 mg (≤ 9 x 80 mg  capsules) LOXO -292 on Day 1 
Additional cohorts (6 subjects per cohort) may be enrolled if it is deemed appro priate to repeat 
any dose level, or to add an interim dose levels or levels (lower than  720 mg) , as determined by 
[CONTACT_893302], depending on the safety and tolerability results from 
the prior cohort(s).  Dosing will not exceed [ADDRESS_1251043] will be assigned a unique identification number upon screening. Subjects who 
complete the study screening assessments and meet all the eligibility criteria will be assigned a 
unique randomization identification number at the time of  the dosing, different from the 
screening number.  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
37
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
All subjects will receive LOXO -292. 
Subjects may be replaced at the discret ion of the Sponsor. 
If replacement subjects are used, the replacement subject number will be 100 more than the 
original (e.g., Subject No. [ADDRESS_1251044] No. 001). 
12.4 Blindin g 
This is an open -label study. 
12.4.1 Dose Escalation Criteria and S toppin g Rule s 
The decision to proceed to the next higher dose administration will be made following the 
review of all pe1tinent safety /tolerability data (e.g., physical exami nations, ECGs , vital signs, 
clinical laborato1y tests, and AEs) from all subjects through a minimum of 48 homs (Day 3) 
postdose for Coho1t 1 and through a minimum of 120 homs postdose (Day 5) for Coho1t 2. 
Dose escalation to the next dose level (i.e., next coh01t) will not take place until the PI [INVESTIGATOR_893284], lower dose, 
coh01t has been demonstrated to pe1mit proceed ing to the next cohort. 
Toget her they will make one of the following dete1minations: 
1. To continue with the study as planned. 
2. To contin ue wi th the study and add additional safety evaluations to subseq uent coho1ts. 
3. In the event of the following occunence: 
One (1) or more subject(s) at a given dose level exper iences a dmg related CTCAE grade 
2'.: 3 toxicity , which is deemed clinically significant by [CONTACT_978] [INVESTIGATOR_893274] , a decision will be made as follows: 
• Cont inue with the study by [CONTACT_893303] ; 
• Adjust to an inte1mediate dose between the cunent dose and the next planned dose; 
• Adjust to an inte1mediate dose between the cmrent dose and the previous lower dose ; 
• D ose administration may be pe1 m itted to contin ue as deemed by [CONTACT_976], in agree ment with 
the Sponsor , where the safety paramete r assesse d does not pose a subject safety risk 
based on safety knowledge from prior LOXO -292 studies. 
4. In the event of the following occunence: 
Two (2) or more subjects in a dose level experie nce a drng related CTCAE grade 2'.: 3 
toxicity, which are deemed clinica lly significant by [CONTACT_978] [INVESTIGATOR_893285] r, a decision will be made as follows: 
Page 36 
LOXO -RET -[ZIP_CODE]; CA27486 ; 16.1.1 Protoco l and Protocol Amendments 38 
CONFIDENTIAL CA27486 (L OXO -RET -[ZIP_CODE]), Final Proto col, 25Jan201 9 
• Dose admini stration may be perm itted to contin ue as planned if deemed acceptable by 
[CONTACT_976], in agreement with the Spon sor, where the safety parameter assessed does not pose a 
subject safety risk based on safety knowledge from prior LOXO -292 studie s; 
• Ev aluate an alternat ive dose lev el; 
• The study may be terminated with no additional dose admini stration to any subjects. 
5. One (1) or more subject(s) in a dose lev el has a drug related SAE , a decision will be made 
as follows: 
• Ev aluate an alternat ive dose lev el; 
• The study will be terminated with no additional dose admini stration to any subjects in 
any cohort. 
Bioanalytical data may be used, if available, to guide dose-escalation decisions or for selection 
of an alternate dose for evaluation , and/or to confirm the sampling sched ule. 
A sufficient period of time will be allowed between Day [ADDRESS_1251045]'s mouth . 
Subject s' hand s will also be verified to ensure that the study drng was ingested. 
Page 37 
LOXO-RET-[ZIP_CODE] ; CA27 486; 16. 1.1 Protocol and Protocol Amendmen ts 39 
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 38 13 STUDY ASSESSMENT
S AND PROCEDURES  
The Study Events Flow Chart ( Section  6) summarizes the clinical procedures to be performed 
at ea
ch visit. Individual clinical procedures are described in detail below. Additional 
evaluations/testing may be deemed necessary by [CONTACT_978] [INVESTIGATOR_50286]/or the Sponsor for 
reasons related to subject  safety.  
For this study, the blood collection for LOXO -[ADDRESS_1251046] time point as possible  and in accordance to the time windows 
provided in the Study Events Flowchart (Section  6).  
The Day [ADDRESS_1251047] be obtained under fasting conditions (i.e., 
prior to the scheduled standard breakfast). 
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.  
13.1 Screening  
Within 28 days prior to dosing, medical history and demographic data, including name, sex, 
age, race, ethnicity, body weight (kg), height (cm), BMI  (kg/m2) and history of tobacco use 
will be recorded . Each subject will have a physical examination, vital sign measurements (heart 
rate, blood pressure, and temperature), 12 -lead ECG, and the laboratory tests of serum 
chemistry, serology, thyroid stimulating hormone, pregnancy (females), FSH (postmenopausal 
females), hematolog y, coagulation,  amylase, lipase, hemoglobin A1c, hepatic function, and 
urinalysis and additional tests as noted in Section  13.2.5. 
13.2 Safety Assessment s 
13.2.1 P
hysical Examination 
Full physical examination s and abbreviated physical examinations will be performed as 
outlined in the Study Events Flow Chart ( Section  6). An abbreviated ph ysical examination 
includes, at the minimum
, examination of respi[INVESTIGATOR_696], cardiovascular, and gastrointestinal 
systems, with the option for further examination of additional systems as necessary based on 
reported symptoms/AEs. Symptom-driven physical examinations may be performed at other 
times, if deemed necessary by [CONTACT_978]  [INVESTIGATOR_1461].  
13.2.2 Vital Signs  
Single me asurements of body temperature, blood pressure, and heart rate, will be measured as 
outlined in the Study Events Flow Chart ( Section  6). Additional vital sign s may be taken at any 
other times, if 
deemed necessary.  
Vital sign measurements should be carried out prior to and as close as possible to having blood 
drawn. Blood pressure and heart rate will be measured using the same arm for each reading. 
Blood pressure, heart rate, and temperature measurements will be performed with subjects in a 
supi[INVESTIGATOR_2547] (at least 5 minutes) ,  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
40
CONFIDE NTIAL CA27486 (LOXO -RET -[ZIP_CODE]), Final Protoco l, 25Jan20 19 
Blood p ressure and heart rate will be m easured at Screening, at Ch eck-in (Day-I), at pre dose 
and at 2 hours ( ± IO minu tes) and 4 ho urs ( ± IO minut es) postdose on Day 1, and once daily on 
each Study Day through EOT or ET (CRU di scharge). 
Body temperature will be measured at Screening, at Ch eck-in (Day-I), at predose, and at the 
EOT or ET (CRU discharge). 
13.2.3 ECG Monitoring 
Single 12-l ead ECGs w ill be perform ed as outlin ed in the Study Events Flow Chait (Section 6). 
Additi onal ECGs m ay be taken at any o ther times, if deemed n ecessary by [CONTACT_978] [INVESTIGATOR_1461]. 
ECGs will be perfmm ed wi th subjects in a supi[INVESTIGATOR_2547] (at least 10 minu tes). All ECG 
tracings will be reviewed by [CONTACT_978] [INVESTIGATOR_1461]. 
ECGs will be m easured at Screening, at Ch eck-in (Day-I), Days 2 and 5 postdose, and at the 
EOT or ET (CRU discharge). ECGs w ill be obtai ned p1ior to and as close as possible to the 
scheduled blood draws if scheduled at the same time. 
13.2.4 Body Weight 
Body weight (kg) will be reported as outlined in the Study Events Flow Chait (Section 6). 
13.2.5 Clinical Laborntor y Tests 
All tests listed below will be perfo1med as outlin ed in the Study Events Flow Chait (Section 6). 
In addition, lab oratory safety tests may be per formed at various unscheduled time points, if 
deemed necessary by [CONTACT_978] [INVESTIGATOR_1660] d esignee . 
Hemato logy Serum Chem istry* 
• Hemoglobin • Blood Urea Nitrogen 
• Hematocri t • Bilimbin (total and direc t) 
• RBCcount • ALP 
• Platelet count • AST 
• RBC distribution width • ALT 
• Mean corpuscu lar hemoglobin • Albumin 
• Mean corpu scular hemoglobin • Calcium 
concentration • Iron 
• Mean corpu scular v olume • Total Protein 
• WBC /leukocy te coun t • Uric Acid 
• WBC /leukocy te differential (absolute and • Sodi um 
percen t) • Potassium 
• Basophil s • Magnesi um 
• Eosinophils • Chloride 
• Lymphocytes • Glucose (fasting) 
• Monoc ytes • Creatine kinase 
• Neutrophils • Creatinine ** 
• Cholesterol (fasting) 
Coagu lation • Triglyceride s (fasting ) 
• Prothrombin Time /International • Phosp homs 
nonnalized ratio • Amyla se • Activated partial thrombopla stin time • Lipase 
• 
Page 39 
LOXO -RET -1805 7; CA27486 ; 16.1.1 Protocol and Protocol Amendme nts 41 
CONF IDENTIAL CA27486 (LOXO -RET -[ZIP_CODE]) , Final Protocol , 25Jan2019 
Urinalysis 
• pH Addi tiona l Tests 
• HIV test**** 
• 
• 
• • 
• 
• 
• 
• 
• 
• Color and appearance 
Specific gravity 
Protein*** 
Gluco se 
Ketone s 
Bili.rubi.n 
Blood *** 
Nitrite *** 
Urobilinogen 
Leukocyte esterase*** • HBsAg**** 
• HCV**** 
• Hemoglobin Al e **** 
• Urine drug screen 
Opia tes 
Opi[INVESTIGATOR_2438] (methadone , oxycodone , and 
fentanyl) 
Amphetamines 
Barbiturate s 
Benzodiazepi[INVESTIGATOR_893286] 
• Urine cotinine 
• Urine alcohol screen 
• Semm pregnancy test 
(for females only) 
• FSH (for postmenopausal females only)**** 
• Thyroid stimulating hormone **** 
Samples for sernm chemistiy will be obtained following a fast of at least 12 hours at Screening and at Check -in 
(Day -1); at other scheduled times, senun chemistly tests will be pe1fonned aft.er at least an [ADDRESS_1251048] be obtained tmder 
fasting conditions 
At Screening and Day - 1, creatinine clearance will be calcula ted using the Cockcroft -Gault formula. 
Ifminaly sis is positive for protein , blood , nitiite and/or leukocyte estera se, a microscopic examination (for red 
blood cells , white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be pe1fonned. 
Perfonned at Screening only; subjec ts who are positi ve for hepatiti s B v i.ms, HCV , or HIV by [CONTACT_893304]. 
13.2.6 Adve 1 ·se Events 
[IP_ADDRESS] Adver se Event D efinition 
An AE means any untoward medical occmTence assoc iated with the u se of a chu g in humans, 
whether or not cons idered chug related. 
A susp ected adverse react ion means any AE for which there is a reaso nable possibility that the 
dmg caused the AE. Reasonable possibility means there is evidence to suggest a causal 
relationship betwee n the ch1 1 g and the AE. 
An AE can therefore be any unfavora ble and unintended sign (including an ab nor m al 
laboratory findin g), sympto m, or disease temporally assoc iated with the use of a med icinal 
(investigat ional) product, whether or not related to the medicinal (investigatio nal) product. 
[IP_ADDRESS] Monitorin g 
Subjects will be mo nitored from Screening ( signing of informed conse nt) until EOS ( or ET if 
the subject discontin ues and does not complete a follow up call) for adve rse reactions to the 
study drugs and/or study proced ures. At t he EOT or ET visit, subjects will be asked h ow they 
Page 40 
LOXO -RET -[ZIP_CODE] ; CA27486 ; 16.1.1 Protocol and Protocol Amendments 42 
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 41 are feeling  prior to ch
eck out from t he CRU . During the EOS/ follow-up phone call, subjects 
will be queried with an open-ended question such as: ‘How have you been feeling since your 
last visit?’ . AEs (whether serious or non-serious), including abnormal laboratory test value(s) , 
abnormal vital signs, and ECG abnormalities deemed clinically significant and assessed as 
related to study drug by [CONTACT_978] [INVESTIGATOR_893287]/or followed through EOT or ET. AEs  which are ongoing at the EOT or ET which are 
assessed as related to study drug by [CONTACT_978] (or designee) will be followed through the EOS. 
AEs which are ongoing at the EOS  which are assessed as related to study drug by [CONTACT_978] [INVESTIGATOR_893288](s) return to normal, or 
acceptable levels, as judged by [CONTACT_978] [INVESTIGATOR_893289].  
Treatment of SAEs will be performed by a physician, either at the CRU  or at a nearby [CONTACT_2360][INVESTIGATOR_322522]. Where appropriate, medical test(s) and/or examination(s) will be performed 
to document resolution of event(s). Outcome may be classified as death related to AE , not 
recovered or not resolved, recovered or resolved, recovered or resolved with sequalae, 
recovering or resolving, or unknown. 
[IP_ADDRESS] Reporting  
AEs and SAEs will be collected beginning at informed consent. AEs will be recorded 
throughout the study (i.e., from signing of the ICF until EOS or ET if the subject discontinues 
and does not complete a follow up call ), either as subject medical history (if the event is 
reported as beginning prior to signing of the ICF or if the event occurs prior to study drug 
administration on Day 1 and is assessed as not related to study procedures by [CONTACT_978] [or 
designee] ) or as AEs  (if the event occurs after signing of the ICF but prior to study drug 
administration on Day 1 and is assessed as  related to study procedures by [CONTACT_978] [or designee], 
or if the event occurs after study drug administration on Day 1 through EOT or ET regardl ess 
of relationship to study drug).  From EOT or ET through EOS, only AEs assessed as related to 
study drug by [CONTACT_978] (or designee) are to be reported. All SAEs that develop from the time of 
ICF signing until EOS  (or ET, if subject discontinues from the study and does not complete the 
follow up call) are to be reported.     
Unless a subject withdraws consent or is withdrawn from the study and does not complete the 
follow up call, all subjects must be followed until the EOS . AEs which are ongoing at the EOS  
which are assessed as  related to study drug may be continued to be followed until the 
symptoms or value(s) return to normal, or acceptable levels, as judged by [CONTACT_978] [INVESTIGATOR_893290]. The PI  (or d esignee)  should use appropriate judgment in 
ordering additional tests as necessary to monitor the resolution of events. The Sponsor may 
request that additional safety tests be performed.  
The PI [INVESTIGATOR_893291] (yes 
[related] or no [unrelated]).  
Unrelated  The time course between the administration of study drug and the 
occurrence or worsening of the AE rules out a causal relationship and 
another cause is suspected  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
43
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 42 Related  The time cour
se between administration of study drug and the occurrence or 
worsening of the AE is consistent with a causal relationship and no other 
cause can be identified  
 
Each sign , symptom, or abnor
mal laboratory value reported as an AE  will b e graded on the 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0 toxicity grading scale. Only abnormal clinical laboratory results or other events 
deemed to be clinically significant by [CONTACT_978] [INVESTIGATOR_893292] . 
Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique 
clinical descriptions of severity for each  AE based on the following general gui deline (NCI 
CTCAE 27 Nov 2017): 
Grade 1  Mild; a
symptomatic
 or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated. 
Grade 2  Moderate; minimal, loca l or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL*. 
Grade 3  Severe or medica lly significant but not immediately life  threatening;  
hospi[INVESTIGATOR_3111]; disabling; 
limiting self -care ADL**.  
Grade 4  Life-threatening cons equences; urgent intervention indicated. 
Grade 5  Death related to AE.  
A Semi -colon indicates ‘or’ within the description of the grade.  
Note: Not all grades
 are appropriate for all AEs. Therefore, some AEs are listed within the CTCAE with fewer than 5  options 
for g rade selection. Grade 5 (death) is not appropriate for some AEs and therefore is not an option.  
ADL= Activities of Daily Living  
* Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone,  managing money, etc.  
** Se lf care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications,  and not 
bedridden.  
[IP_ADDRESS] Serious Adverse Event  
If any AEs are serious, as defined by  [CONTACT_2165] ( FDA ) Code of 
Federal Regulations (CFR), Title 21, special procedures will be followed. All SAEs will be 
reported to the Sponsor or designee via fax or e- mail within [ADDRESS_1251049] awareness of the 
event, whether or not the serious event(s) are deemed drug -related. All serious event report ing 
will adhere to 21 CFR  312.32 for Investigational New Drugs (IND) and to the Guidance for 
Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE, dated 
December 2012. Any event that meets the criteria of a suspected unexpected seri ous adverse 
reaction (S[LOCATION_003]R) will be reported to the Institutional Review Boards/ Independent ethics 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
44
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 43 committee  (IRB/IEC ) ac
cording to site /CRU  policy by [CONTACT_737] (or designee) and to 
regulatory authorities by [CONTACT_1034] (or Sponsor designee) according to regulatory authority 
requirements. Refer to Reference Safety Information (RSI) in the current IB for expected 
adverse reactions.  
A SAE  is any AE or suspected adverse reaction that in the view of either the PI (or designee) 
or Sponsor, results in any of the following outcomes: Death, a life-threatening AE, inpatient 
hospi[INVESTIGATOR_1081], a persistent or significant incapacity 
or disability, or a congenital anomaly/birth defect . Important medical events that may not result 
in death, be life-threatening, or require hospi[INVESTIGATOR_708], based 
upon appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in the above definition. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
Life-threatening is defined as an AE or suspected adverse reaction that in the view of the PI (or 
designee) or Sponsor, places the patient or subject at immediate risk of death. It does not 
include an AE or suspected adverse reaction that, had it occurred in a more severe form, might 
have caused death. 
All SAEs must be reported on a SAE Report Form provided by [CONTACT_679364] e-mail to the Sponsor listed in Section  [ADDRESS_1251050] awareness of the event.   
When us
ing the SAE efax (+ [PHONE_14068]) a cover page including study identification 
number and study drug product (i.e., LOXO- 292) is required. Alternatively, an email can be 
sent to [EMAIL_814]. 
The PI [INVESTIGATOR_893293] . However, if the PI [INVESTIGATOR_679316], and that event is deemed 
associated with the use of study drug, he/she should promptly document and report the event. 
The PI [INVESTIGATOR_679317] -up regarding the 
SAE. Although not considered an AE per se, the Sponsor must be notified of any subject or 
subject’s partner who becomes pregnant during the study at any time between Screening until 
90 days after study drug a dministration on Day 1. 
13.3 Pharmacokinetic Assessment s 
13.3.1 Blood Sampling and Processing  
For all subjects, blood samples for the determination of LOXO- 292 will be collected at 
scheduled time points as delineated in the Study Events Flow Chart ( Section  6). Tubes will be 
identified with a barc
ode using an appropriate label. 
Instruction s for blood sampling, collection, processing, and sample shipment will be provided 
separately.  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
45
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 44 Blood collections p
erformed  outside of the sample collection windows as defined in the Study 
Events Flow Chart ( Section  6) will be considered deviations. 
13.3.[ADDRESS_1251051] cohort and may be used for future 
analyses of plasma for metabolite(s) formation . Tubes will be identified with a barcode using 
an appropriate label. No diseases/conditions, deoxyribonucleic acid, or ribonucleic acid  will be 
the focus of these analyses. The analyses will focus on assessing potential metabolites. Any 
additional research on these samples unspecified by [CONTACT_893305]. Samples will not be submitted to a public database.   
The sponsor and contract research organizations involved in the clinical conduct, bioanalytical 
analyses and pharmacokinetics and statistical analysis of the data will  have access to the 
samples and /or the data that resulted from the analysis, if performed.  
By [CONTACT_12568], subjects agree to the possible future analysis of these samples; however, at 
any time, the subjects can contact [CONTACT_893306] -292 PK assessments required to meet the primary objective of the study are 
completed.  
13.3.3 Pharmacokinetic Parameters  
PK parameters for plasma LOXO-292 will be calculated as follows, as appropriate:   
AUC0 -t: 
 The area under the concentration -time curve, from time  [ADDRESS_1251052] 
observed non- zero concentration , as calculated by [CONTACT_47389]. 
AUC0 -24: 
 The area under the concentration -time curve, from time  0 t o Hour 24, as 
calculated by [CONTACT_39441].  If the 24-hour plasma 
co
ncentration is missing,  BLQ or not reportable, then this parameter 
cannot be calculated.  
AUC0 -inf: The area under the concentration -time curve from time  [ADDRESS_1251053] measurable plasma concentr ation to the elimination rate 
constant. 
AUC%extrap:  Percent of AUC0 -inf  extrapolated, represented as 
(1 - AUC0 -t/AUC0 -inf)*100. 
CL/F:  Apparent total plasma clearance after oral (extravascular) 
administration, calculated as Dose/AUC0 -inf. 
Cmax:  Maximum observed concentration. 
Tmax:  Time to reach Cmax. If the maximum value occurs at more than one 
time point, Tmax is defined as the first time point with this value.  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
46
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 45 Kel: Apparent first -order terminal elimina tion rate constant calculated from a 
semi -log plot of the plasma concentration versus time curve. The 
parameter will be 
calculated by [CONTACT_47390] -squares regression analysis 
using the maximum number of points in the terminal log- linear phase 
(e.g., three or more non- zero plasma concentrations).  
t½: Apparent first -order terminal elimin ation half -life will be calculated as 
0.693/ Kel. 
Vz/F:  Apparent volume of distribution during the terminal elimination phase 
after oral (extravascular) administration, calculated as 
(Dose/AUC0 -inf) x Kel . 
No va
lue for Ke l, AUC%extrap, AUC0 -inf, CL/F, Vz/F, or t½ will be reported for cases that 
do not exhibit a terminal log linear phase in the concentration time profile.  
No PK parameters will be calculated for subjects with 2 or fewer consecutive time points with 
detectable concentrations.  
Individual and mean plasma concentration time curves (both linear and log- linear) will be 
included in the final Clinical Study Report. 
13.3.4 Analytical Method 
Samples will be analyzed for plasma LOXO -292 using validated bioanalytical m ethods. 
Samples from subjects to be assayed are specified in Section  14.2. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
47
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 46 13.4 Blood Volume 
Drawn for Study Assessments  
Table 2: Blood Volume during the Study  
Sample Type  Number of 
Time Points  Approximate 
Volume per Time 
Point* (mL)  Approximate 
Sample Volume 
Over Course of 
Study (mL)  
Screening laboratory safety tests (including 
hematology, serum c
hemistry, coagulation, 
serology , thyroid stimulating hormone, FSH 
(for postmenopausal female subjects only) and 
serum pregnancy (for female subjects only)  1 16 16 
Screening Hemoglobin A1c  1 4 4 
On-study hematology , serum chemistr y, and 
coagulation  (and serum pregnancy  [for female 
subjects only]  if scheduled at same time)  4 16 64 
Blood for LOXO -292 PK 21 4 84 
Total Blood Volume (mL)  168* 
* Represents the largest collection tube that may be used for this (a smaller tube may be used).  
** If additional saf
ety or PK analysis is necessary to obtain sufficient plasma/serum for analysis, additional 
blood may be obtained (up to a maximum of 50 mL).  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
48
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251054] Operating Procedures, 
which are written based on the principles of GCP . 
14.1 Sample Size Determination  
The sample size chosen for this study was selected without stati stical considerations. It has 
been determined adequate to meet the study objectives . 
14.2 Population for Analyses 
Safety Population: All subjects who received at least one dose of the study drug will be 
included in the safety evaluations. 
PK Population: Plasma samp
les from all subjects will be assayed even if the subjects do not 
complete the study. PK population will comp rise all subjects who comply sufficiently with the 
protocol and display an evaluable PK profile (e.g., exposure to treatment, availability of 
measurements and absence of major protocol violations). 
14.3 Statistical Analyses 
Detailed methodology for summary and statistical analyses of the data collected in this study 
will be documented in a Statistical Analysis Plan (SAP). The SAP will be prepared by [CONTACT_893307]. This document may modify the plans outlined in the 
protocol; however, any major modifications of the primary endpoints definition and/or its 
analysis will also be reflected in a protocol amendment. Additional statistical analyses other 
than those described in this section may be performed if deemed appropriate.  
14.3.[ADDRESS_1251055].  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA®) and 
summarized by [CONTACT_679366]. A by-subject AE data 
listing including verbatim term, coded term, treatment, severity, and relationship to treatment 
will be provided.  
Safety data including ECGs, physical examinations, vital signs assessments, clinical laboratory 
results, will be summarized by [CONTACT_25322].  
Descriptive statistics using appropriate summary statistics will be calculated for quantitative 
safety data as well as for the difference to baseline, when appropriate.  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
49
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251056].  
14.3.2 Pharmacokinetic Analyses  
[IP_ADDRESS] Descriptive Statistics  
Values will be calculated for the plasma concentrations and the PK parameters listed in 
Section  13.3.2 for LOXO -292 using appropriate summary statistics to be  fully outlined in the 
SAP.   
Mean and individual LOXO -292 concentration -ti me profiles will be presented on linear and 
semi -log scales. Any additional PK analysis will be outlined in the SA P. 
Dose proportionality may be assessed using the power model approach, as appropriate. Details 
on this regression analysis will be outlined in the SAP.  
 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
50
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251057]  
This protocol will be reviewed by [CONTACT_426429], and the study will not start until the IRB has 
approved the protocol or a modification thereof. The IRB will be constituted and operate in 
accordance with the principles and requirements described in the US Code of Feder al 
Regulations (21 CFR  Part 56) and will be compliant to The International Council  on 
Harmonisation (ICH) guidelines. 
15.1.[ADDRESS_1251058] of the Study  
This research will be carried out in accordance with the protocol, US Code of Federal 
Regulations, 21 CFR  Parts  50, 56, and 312, the ethical principles set forth in the Declaration of 
Helsinki, GCP, and the ICH harmonized tripartite guideline regarding GCP (E6[R2] Good 
Clinical Practice: Integrated Addendum to E6 [R1], Nov  2016).  
15.1.[ADDRESS_1251059] Information and Consent  
The purpose of the study, the procedures to be carried out and the potential hazards will be 
described to the subjects in non-technical terms. Subjects will be required to read, sign and date 
an ICF summa rizing the discussion prior to Screening, and will be assured that they may 
withdraw from the study at any time without jeopardizing their medical care.  
Subjects will be given a copy of their signed ICF. 
15.1.4 Confidentiality  
All members of the Investigator’s staff have signed confidentiality agreements. By [CONTACT_130720], the Investigator and investigational staff will regard all information provided by [CONTACT_859005].  
The Investigator must guarantee the privacy of the subjects taking part in the study. Subjects 
will be identified throughout documentation and evaluation by a unique subject study number. 
Throughout the study, a subject’s source data will only be linked to the Sponsor’s clinical 
study database or documentation via a unique identification number. Any information 
concerning the subjects (clinical notes, identification numbers, etc.) must be kept on file by [CONTACT_893308], IRB, or regulatory 
authorities for the purposes of trial monitoring, auditing or official inspections. As required, in 
the case of an event where medical expenses are the responsibility of the Sponsor, personal 
information i.e., full name, social security details etc. , may be released to the Sponsor. 
Appropriate precautions will be taken to maintain confidentiality of medical records and 
personal information in strictest confidence and in accordance with local data. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
51
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251060] operating procedures are available for all activities performed at Celerion  relevant to 
the quality of this study. Designated personnel of Celerion will be responsible for 
implementing and maintaining quality assurance (QA) and quality control systems to ensure 
that the study is conducted, and that data are generated, documented and reported in 
compliance with the study protocol, GCP and GLP  requirements as well as applicable 
regulatory requirements and local laws, rules and regulations relating to the conduct of the 
clinical study.  
The Clinical Study Report will be audited by [CONTACT_893309]. 
Edit checks are then performed for appropriate databases as a validation routine using SAS® or 
comparable statistical program to check for missing data, data inconsistencies, data ranges , etc. 
Corrections are made prior to database lock.  
15.[ADDRESS_1251061] Access to Source Data/Documents  
Celerion  will ensure that the Sponsor, IRB,  and inspection by [CONTACT_893310] , source data/documents, and reports for the 
purpose of monitoring and auditing (ICH[E6] 5.1.2 & 6.10). In the event that other 
study-related monitoring should be done by [CONTACT_121298], they will be required to sign a 
confidentiality agreement prior to any monitoring and auditing.  
15.5 Drug Supplies, Packaging and Labeling  
The Sponsor will supply sufficient quantities of the LOXO-292 capsules to allow completion 
of this study. The lot numbers and expi[INVESTIGATOR_1659] (where available) of the study drugs 
supplied will be recorded in the final Clinical Study Report. 
Records will be made of the receipt and dispensing of the study drugs  supplied. At the 
conclusion of the study, any unused study drug s will be retained by [CONTACT_47365] , returned to the 
Sponsor or designee, or destroyed, as per Sponsor instructions. If no supplies remain, this fact 
will be documented in the pharmacy product accountability records. 
15.[ADDRESS_1251062] CRFs will be supplied. CRFs are produced  and may be printed off from the 
database and made available to the designated study team members.  The CRFs are also  stored 
electronically. Each CRF book is reviewed and signed by [CONTACT_978]. The final signed CRFs are 
provided to the Sponsor on CD. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
52
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page [ADDRESS_1251063]. These documents 
should be retained for a longer period however if required by [CONTACT_165032]. It is the responsibility of the Sponsor to 
inform Celerion as to when these documents no longer need to be retained. 
15.7 Report Form at 
According to the ICH Harmonized Tripartite Guideline (Organization of the Common 
Technical Document for the Registration of Pharmaceuticals for Human Use M4 and the 
ICH M2 Expert Working Group), the final Clinical Study Report will be written according to 
the ICH  E3 Guideline (Structure and Content of Clinical Study Reports).  
15.[ADDRESS_1251064] party without the prior written consent of the Sponsor.  
The data generated by [CONTACT_117607]. This confidential information may be published only in collaboration with 
participating personnel from the Sponsor or upon Sponsor’s written consent to publish the 
article.  
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
53
CONFIDENTIAL  CA2 7486 ( LOXO -RET -[ZIP_CODE]), Final Protocol , 25Jan2019 
 
Page 52 16 REFERENCES  
LOXO -292. Inv
estigator’s Brochure. Loxo Oncology, Inc. Version 4.0. 01- Oct-2018. 
National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), 
Revised: Nov-2017 (v 5.0). Available at: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_
Reference_8.5x11.pdf. 
LOXO-RET-[ZIP_CODE]; CA27486; 16.1.1 Protocol and Protocol Amendments
54